Pascal Soriot, chief executive officer of Astrazeneca Plc, poses for a photograph before an interview in London, U.K., on Monday, Sept. 4, 2017. Soriot said hes worried about the lack of progress in negotiations between the U.K. and the European Union on their future ties, which could impede sales of drugs in foreign markets after Brexit. Photographer: Chris Ratcliffe/Bloomberg via Getty Images
FILE PHOTO: A pedestrian crosses a road near AstraZeneca Plc's factory in Macclesfield, U.K., on Thursday, July 4, 2013. Pfizer Inc. proposed buying AstraZeneca Plc for about 58.8 billion pounds ($98.7 billion) in what would rank as the biggest-ever U.K. takeover and continues to be interested in a deal after getting spurned. Photographer: Paul Thomas/Bloomberg via Getty Images
JOHANNESBURG, CAMBRIDGESHIRE - MAY 15: Nexiam (Generic name - Esomeprazole) made by the pharmaceutical firm AstraZeneca are displayed in a Pharmacy on May 15, 2014 in Johannesburg, South Africa. The proposed takeover by American pharmaceutical giant Pfizer of its British rival AstraZeneca has led to the UK Business Secretary Vince Cable addressing Parliament to affirm the government's commitment to securing British science jobs. (Photo by Christopher Furlong/Getty Images)
The Pfizer Inc. company logo and the AstraZeneca Plc company logo, top, are seen on boxes of pharmaceutical products produced by the drug makers in this arranged photograph taken in London, U.K., on Friday, May 2, 2014. AstraZeneca Plc rejected Pfizer Inc.'s sweetened takeover proposal, saying the 63.1 billion-pound ($106.5 billion) offer fails to recognize the value of the promising experimental medicines under development by the U.K.'s second-biggest drugmaker. Photographer: Chris Ratcliffe/Bloomberg via Getty Images
AstraZeneca PLC signage is displayed on a monitor on the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Monday, Sept. 12, 2016. U.S. stocks rebounded after the biggest rout since June wiped about $500 billion from the value of equities, while Treasury yields held near two-month highs before the Federal Reserve's Lael Brainard official speaks. Emerging-market assets slumped. Photographer: Michael Nagle/Bloomberg via Getty Images
